Shiren Sun1, Wang Di1, Rong Li1, Xiaoxia Yang1, Qin Jia1, Chunmei Liu1, Feng Ma2,3. 1. Department of Nephrology, Xijing Hospital, Fourth Military Medical University, No. 127 Changle West Road, Xi'an, 710032, Shaanxi, China. 2. Department of Nephrology, Xijing Hospital, Fourth Military Medical University, No. 127 Changle West Road, Xi'an, 710032, Shaanxi, China. 28186432@qq.com. 3. Department of Nephrology, Xi'an Jiao Tong University-Affiliated Honghui Hospital, Xi'an, 710054, Shaanxi, China. 28186432@qq.com.
Abstract
PURPOSE: IgA nephropathy (IgAN) patients with monoclonal light-chain deposition may be at potential risk of hematological progression. However, whether the clinical characteristics of the patients with predominant lambda or kappa light-chain deposition were consistent with monoclonal light-chain deposition is limited to anecdotes. METHODS: We retrospectively studied patients in whom immunofluorescence showed IgA-alone deposits (n = 617) between January 2016 and January 2020. We divided the patients into two groups, the predominant lambda or kappa light-chain deposition group and the control group. Predominant lambda or kappa light-chain deposition was defined as the deposition intensity of kappa or lambda being + - and the other deposition intensity being ≥ 2 + . RESULTS: Nineteen patients had predominant lambda or kappa light-chain deposition. The patients had a median age of 32 years. The median proteinuria was 0.9 g/day. The median eGFR was 79.8 ml/min per 1.73 m2. Two patients had a mildly abnormal FLC ratio, but serum immunofixation electrophoresis showed polyclonal immunoglobulin. Eighteen patients showed lambda light chain-dominated deposition. In electron microscopy, organized structures in dense deposits were not observed in all patients. Nine patients with proteinuria ≥ 1.0 g/day received corticosteroids and immunosuppressants. The median follow-up time was 21 months. The rate of proteinuria remission was 50%. The clinical and pathological characteristics and outcomes were not significantly different between the predominant lambda or kappa light-chain deposition group and the control group. CONCLUSION: The result for IgAN patients with predominant kappa/lambda light-chain deposition seemed to be the same as that of IgAN patients with light-chain codeposition. However, as this was a single-center study with a small size, further multicenter studies and long-term follow-up are needed to confirm our findings.
PURPOSE: IgA nephropathy (IgAN) patients with monoclonal light-chain deposition may be at potential risk of hematological progression. However, whether the clinical characteristics of the patients with predominant lambda or kappa light-chain deposition were consistent with monoclonal light-chain deposition is limited to anecdotes. METHODS: We retrospectively studied patients in whom immunofluorescence showed IgA-alone deposits (n = 617) between January 2016 and January 2020. We divided the patients into two groups, the predominant lambda or kappa light-chain deposition group and the control group. Predominant lambda or kappa light-chain deposition was defined as the deposition intensity of kappa or lambda being + - and the other deposition intensity being ≥ 2 + . RESULTS: Nineteen patients had predominant lambda or kappa light-chain deposition. The patients had a median age of 32 years. The median proteinuria was 0.9 g/day. The median eGFR was 79.8 ml/min per 1.73 m2. Two patients had a mildly abnormal FLC ratio, but serum immunofixation electrophoresis showed polyclonal immunoglobulin. Eighteen patients showed lambda light chain-dominated deposition. In electron microscopy, organized structures in dense deposits were not observed in all patients. Nine patients with proteinuria ≥ 1.0 g/day received corticosteroids and immunosuppressants. The median follow-up time was 21 months. The rate of proteinuria remission was 50%. The clinical and pathological characteristics and outcomes were not significantly different between the predominant lambda or kappa light-chain deposition group and the control group. CONCLUSION: The result for IgAN patients with predominant kappa/lambda light-chain deposition seemed to be the same as that of IgAN patients with light-chain codeposition. However, as this was a single-center study with a small size, further multicenter studies and long-term follow-up are needed to confirm our findings.
Authors: Marguerite Vignon; Camille Cohen; Stanislas Faguer; Laure-Hélène Noel; Celine Guilbeau; Marion Rabant; Sarah Higgins; Aurélie Hummel; Alexandre Hertig; Hélène Francois; Moglie Lequintrec; Eve Vilaine; Bertrand Knebelmann; Jacques Pourrat; Dominique Chauveau; Jean-Michel Goujon; Vincent Javaugue; Guy Touchard; Khalil El Karoui; Frank Bridoux Journal: Kidney Int Date: 2017-01-06 Impact factor: 10.612
Authors: Hernán Trimarchi; Jonathan Barratt; Daniel C Cattran; H Terence Cook; Rosanna Coppo; Mark Haas; Zhi-Hong Liu; Ian S D Roberts; Yukio Yuzawa; Hong Zhang; John Feehally Journal: Kidney Int Date: 2017-03-22 Impact factor: 10.612
Authors: Kar Neng Lai; Sydney C W Tang; Francesco Paolo Schena; Jan Novak; Yasuhiko Tomino; Agnes B Fogo; Richard J Glassock Journal: Nat Rev Dis Primers Date: 2016-02-11 Impact factor: 52.329